Rein Therapeutics, Inc.
RNTXDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Aug 13, 2026
8dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
RNTX Earnings Report
EPS Est: $-0.27 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How RNTX's past catalysts played out
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Rein Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Rein Therapeutics, Inc.'s (RNTX) pipeline across Phase 2. Its lead program is LTI-03 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Rein Therapeutics, Inc.'s next FDA catalyst?→
Rein Therapeutics, Inc.'s (RNTX) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RNTX biotech catalysts?→
Add RNTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Rein Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.